Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters.

In our first blog, we explored how sterile fill finish operations are designed around European Union Good Manufacturing Practice (EU GMP) Annex 1 principles to satisfy strict regulatory expectations for contamination control. Establishing sterile conditions at the filling machine is only part of the challenge, with product quality and batch consistency depending heavily on the upstream steps where the active drug formulation is prepared and held before transfer. 

One of the most persistent upstream challenges in contemporary manufacturing is process inconsistency. This variability often stems from scaling a formulation before the molecule’s physical and chemical sensitivities are fully characterized. Moving quickly from the laboratory to pilot scale can leave gaps in knowledge regarding how a drug behaves under real-world conditions, how sensitive it is to mechanical stress and how much process variability it can tolerate. 

What is precision formulation handling?

In parenteral manufacturing, formulation is the precise physical and chemical compounding of a drug substance into its final bulk form. This process requires active management of critical process parameters (CPPs), including mixing speed and times, process and hold temperatures, filtration pressures and in-process parameters such as pH and dissolved oxygen content, to preserve the drug’s molecular characteristics. 

Under regulatory frameworks such as Annex 1, upstream handling must be designed to minimize the risk of contamination [1]. In the past, processing often relied on open vessels or manual transfers, which introduced atmospheric risks and potential contamination. Modern precision handling uses fully closed systems and single-use technologies with automated monitoring to isolate the product from the environment to ensure the drug product remains stable and uncontaminated as it moves from preparation to the filling line. 

How does precision formulation handling work?

The process begins with the facility layout, where formulation suites are co-located with aseptic filling operations to reduce transfer times and modular suites are optimized for single-use systems. This architectural approach enables a clean unidirectional flow for personnel, materials and product to minimize human intervention and sterility risks while maximizing operational efficiency.

Beyond spatial layouts, modern process engineering must protect the drug’s molecular structure during compounding. For shear-sensitive biologics, this protection requires magnetically driven levitation impellers that eliminate heat-generating shafts and seals. Similarly, safeguarding chemically sensitive active ingredients from degradation involves maintaining precise atmospheric controls within the formulation vessel. Implementing active nitrogen overlays and nitrogen sparging processes, alongside continuous inline monitoring of dissolved oxygen and pH, helps maintain the bulk product’s stability throughout the formulation and hold period.

Finally, validating these processes requires testing the formulation on production-scale equipment rather than relying solely on laboratory-scale observations. These initial engineering runs expose the drug to production-scale conditions, allowing developers to set realistic process boundaries well before formal GMP production begins.

Who is precision formulation handling for?

Upstream precision handling is highly beneficial for several distinct types of drug development programs and stages of the product lifecycle:

• Complex and sensitive formulations: High-value assets such as monoclonal antibodies and recombinant proteins are vulnerable to the mechanical forces in standard mixing [2]. Small molecules prone to oxidation also require strict environmental controls to prevent chemical degradation [3]. 
• Programs transitioning to commercial scale: Replicating a clinical formulation at commercial scale introduces unexpected variability. Precision handling addresses this issue by reproducing formulation conditions across different manufacturing scales. Replicating these parameters eliminates scale-up guesswork and secures a predictable path toward validation.
• Early-stage development programs: Developing a robust compounding process early prevents costly process redesigns before a formulation is locked. Early precision handling helps developers identify molecular sensitivities, document realistic operating limits and design processes with industrial machinery in mind. This foresight ensures the bulk drug remains stable and behaves predictably inside its target delivery device.

What are the benefits of upstream control?

When upstream parameters are poorly defined, the instability reveals itself loudly during sterile fill finish. Inconsistencies appear as unexpected yield loss during processing alongside batch-to-batch differences in product chemistry. Beyond simple operational delays, these processing failures can escalate to complete batch rejection, lost commercial materials and compromised patient safety. 

If a process arrives with technical gaps, structured risk assessments help secure the manufacturing timeline. Implementing a phased transition that moves from engineering runs to validation before starting GMP production provides a clear framework for scale-up. Applying enhanced monitoring during early batches and establishing clear contingency plans further mitigates uncertainty. This proactive quality mindset reduces the potential for deviations, investigations and delayed launch timelines.

Enhancing parenteral performance at Bridgeton

Kindeva has integrated these upstream precision capabilities into our state-of-the-art sterile fill finish facility in Bridgeton, Missouri. To protect sensitive bioproducts during compounding, the Bridgeton formulation suites combine single-use technology with levitating magnetic drive impellers to establish an ultra-low-shear mixing environment. These co-located modular suites accommodate varying program scales with formulation vessels ranging from 10 to 500 liters. 

As an extended member of your team, Kindeva adds value by translating complex development processes into highly manufacturable designs. We strengthen CPPs and ensure the final formulation works seamlessly with your container-closure system. Our Bridgeton facility brings together the advanced infrastructure and technical expertise needed to de-risk your commercial path. 

In our next blog, we will examine how modern high-speed filling lines maintain this precise control as the drug product is filled into vials, syringes or cartridges.

References

1. European Commission. “Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use – Annex 1: Manufacture of Sterile Medicinal Products.” 2022. https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf 
2. Li, Jinjiang, Mary E. Krause, et al. “Interfacial Stress in the Development of Biologics: Fundamental Understanding, Current Practice, and Future Perspective.” The AAPS Journal. 21.44 (2019): Web. https://link.springer.com/article/10.1208/s12248-019-0312-3 
3. Gabri, Alen,  Žiga Hodnik, Stane Pajk. “Oxidation of Drugs during Drug Product Development: Problems and Solutions.” Pharmaceutics. 14.325 (2022): Web. https://www.pharmaexcipients.com/wp-content/uploads/2022/02/Oxidation-of-Drugs-during-Drug-Product-Development-Problems-and-Solutions.pdf